<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/250728-a-compound-of-pyridinium-series by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 14:16:41 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 250728:A COMPOUND OF PYRIDINIUM SERIES</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">A COMPOUND OF PYRIDINIUM SERIES</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>The invention discloses novel compounds of the pyridinium series useful for the management of diabetes and aging-related vascular complications, including kidney disease, nerve damage, atherosclerosis, retinopathy, dermatological disorders and discoloration of teeth, by breaking preformed AGE, of the general formula I, or pharmaceutically acceptable salts thereof,</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>The present invention relates to a new class of compounds of pyridiuium<br>
series and to their use in treatment of diabetes and related illnesses. More<br>
particularly the invention relates to compounds of this series, methods for their<br>
preparation, pharmaceutical composition containing these compounds and their use<br>
in the treatment of complications of diabetes mellitus. The compounds of this series<br>
exhibit AGE breaking activity, which is essential for the treatment of diabetic and<br>
aging-related complications including kidney disease, nerve damage,<br>
atherosclerosis, retinopathy and dermatological conditions. The invention also<br>
extends to the method of reversing the discoloration of teeth resulting from<br>
nonenzymatic browning in the oral cavity which comprises administration of an <br>
amount effective to reverse pre-formed advanced glycosylation crosslinks.	<br>
Maillard in 1912 found that reducing sugars, such as glucose and ribose react<br>
with proteins to form brown pigments. Further studies have shown that this is an<br>
irreversible non-enzymatic reaction, which occurs in several natural systems<br>
including stored foodstuff. Maillard reaction occurs in two stages, early and<br>
advanced. Initially, proteins react with glucose to form stable Amadori products,<br>
which subsequently cross-links to form advanced glycation end products (AGE), In<br>
most cases, the formation of AGE also accompanies browning of the proteins and<br>
increase in the fluorescence.<br><br>
In diabetes, where blood glucose level is significantly higher than normal, the<br>
reaction of glucose with several proteins such as haemoglobin, lens crystallin and<br>
collagen, gives rise to the formation of AGE, which in turn, is responsible for the<br>
complications associated with diabetes, such as nephropathy, microangiopathy,<br>
endothelial dysfunction and other organ dysfunctions. In addition, the activity of<br>
several growth factors, such as basic fibroblast growth factor, is also impaired.<br>
AGE products, unlike normal proteins in tissue, have a slower rate of turnover and<br>
replenishment. It has been reported that AGE products may in fact elicit a complex.<br>
immunological reaction involving RAGE (Receptor for Advanced Glycation End<br>
Products) receptors and activation of several incompletely defined immunological<br>
processes. It has been documented that diabetes with evidence of microangiopathy<br>
and macroangiopathy also show evidence of oxidative stress, the mechanism of<br>
which has not been elucidated.<br>
In vitro AGE formation can be studied in the laboratory by incubating<br>
reducing sugars, such as ribose or glucose with bovine serum albumin. AGE<br>
formation can be detected by increase in the fluorescence or increased cross<br>
reactivity with anti-AGE antibodies. The increase in fluorescence seems to precede<br>
formation of AGE specific antigenic epitopes. This increase in fluorescence is used<br>
to monitor the increased AGE formation in vitro (Brownlee M et al, Science 1986;<br>
232:1629-1632). In addition to the increase in the fluorescence, one of the most<br><br>
important features of in vitro AGE formation is the formation of antigenic epitopes<br>
that are specific to AGE and not to the native proteins. Therefore, it is possible to<br>
raise antibodies against advanced glycation end products of one protein and use<br>
them to detect AGE formation in other proteins. This has served as an important<br>
analytical tool in AGE research.<br>
Due to the clinical significance of AGE formation, many approaches are<br>
being used to diagnose, prevent, or revert AGE formation in the body. The<br>
formation of AGE could be inhibited by reacting with an early glycosylation<br>
product that results from the original reaction between the target protein and<br>
glucose. The inhibition was believed to take place as the reaction between the<br>
inhibitor and the early glycosylation product appeared to interrupt the subsequent<br>
reaction of the glycosylated protein with additional protein material to form the<br>
cross linked late stage product. Compounds like aminoguanidine act to inhibit AGE<br>
formation by such mechanism.<br>
The formation of AGE on long-lived proteins is also associated with cross-<br>
linking of these proteins. The AGE derived protein cross-links have been shown to<br>
be cleaved by compounds like N- phenacyl thiazolium bromide (PTB), which reacts<br>
with and cleaves covalent, AGE derived protein cross links (Vasan et al. Nature<br>
1996; 382: 275-278 ; US 5,853,703, Date of Patent : Dec. 29, 1998). The<br>
mechanism of reducing the AGE content in tissues is expected to take place<br><br>
relatively rapidly, in contrast to aminoguanidine, which acts slowly by its very<br>
nature of mechanism of action. This current specification is related to compounds<br>
of pyridinium class, which break pre-formed AGE, like PTB, and in some cases<br>
even more effectively by than PTB.<br>
The main objective of the present invention is to provide a new class of<br>
compounds of the pyridinium series which are useful for the management of<br>
diabetes and aging related vascular complications and particularly in the treatment<br>
of complications of diabetes mellitus and other aging related conditions including<br>
kidney disease, nerve damage, atherosclerosis, retinopathy and dermatological<br>
conditions. The invention also extends the method to reverse the discoloration of<br>
teeth resulting from nonenzymatic browning in the oral cavity which comprises<br>
administration of an amount effective to reverse the pre-formed advanced<br>
glycosylation crosslinks, etc.<br>
Another object of the present invention is to provide compounds of the<br>
pyridinium series, which exhibit AGE breaking activities.<br>
Yet another object of the present invention is to provide a method of<br>
preparation of compounds of the pyridinium series which exhibit AGE breaking<br>
activities.<br><br>
Still another object of the invention is to provide pharmaceutical<br>
compositions with a new class of compounds of the pyridinium series according to<br>
the invention and their pharmaceutically acceptable salts in combination with<br>
suitable carriers, solvents, excepients, diluents and other media normally employed<br>
in preparing such compositions.<br>
Still another object of the invention is to provide a method of treatment of a<br>
diabetic patient by administration of the compounds of the invention, either singly<br>
or in combination with drugs for anti-diabetic therapy, or pharmaceutically<br>
acceptable salts thereof in required dosage in admixture with pharmaceutically<br>
acceptable diluent, solvent, excepients, carriers or other media as may be<br>
appropriate for the purpose.<br>
The present invention provides for a new class of AGE breakers, of general formula<br>
I, <br>
6<br><br>
wherein<br>
R1 is -R4-R5 or -N(R7) N (R7) R9;<br>
R4 is selected from the group consisting of -N(R7)R6O, -N(R7)R6N(R7)-, OR6O,<br>
and -OR6N(R7)-,<br>
where R6 is alkyl;<br>
R5 15 selected from the group consisting of alkyl, alyl including heteroaryl,<br>
-COR7, SO2R7, -C(S) NHR7, -C(NH)NHR7, -COR10,<br><br>
where R7 is selected from the group consisting of H, alkyl and aryl including<br>
heteroaryl provided R7 might be different for R1 and R3 in the same compound;<br>
R2 is selected from the group consisting of F, Cl, Br, I, OR7, NO2, alkyl, aryl<br>
including heteroaryl, formyl, acyl, C(O)NR7R10, C(O)OR7, NR7RI0, N=C(R7)(R10),<br>
SR7, SO2NH2) SO2 alkyl and SO2aryl,<br>
and m is 0, 1 or 2;<br>
R3 is selected from the group consisting of R7, OR7, N(R7) (R10), N=C(R7) (R10),<br>
N(R7) N(R7) (R10), N(R7) N=C(R7) (R10) and CH(R7)C(0)R8<br><br>
where R8 is selected from the group consisting of R7, OR7 and NR7R10;<br>
R9 is selected from the group consisting of hydrogen, alkyl, aryl including<br>
heteroaryl, C(O)R10, -SO2R10, -C(S)NHR,0, -C(NH) NH (R10) and -C(O) NHR,0,<br>
R10 is selected for the group consisting of H, alkyl or aryl including heteroaryl and<br>
in each case optionally different from substituent R10, provided R10 might be<br>
different for R1 and R3 in the same compound;<br>
X is selected from group consisting of a halide ion, acetate ion, perchlorate ion,<br>
sulfonate ion, oxalate ion, citrate ion, tosylate ion, maleate ion, mesylate ion,<br>
carbonate ion, sulfite ion, phosphoric hydrogen ion, phosphonate ion, phosphate<br>
ion, BF4" and PF6;<br>
with proviso that,<br>
(i) when two alkyl groups are present on the same carbon or nitrogen, they are<br>
optionally linked together to form a cyclic structure and<br>
(ii) the nitrogen of heteroaryl ring of R10, when present, is optionally quaternized<br>
with compound such as X-CH2C(O)-R;,<br>
As used herein, "alkyl" refers to an optionally substituted hydrocarbon group<br>
joined by single carbon-carbon bonds and having 1 to 8 carbon atoms joined<br>
together. The alkyl hydrocarbon group may be linear, branched or cyclic, saturated<br>
or unsaturated. The substituents are selected from F, Cl, Br, 1, N, S, O and aryl.<br>
Preferably, no more than three substituents are present.<br><br>
As used herein "aryl" refers to an optionally substituted aromatic group with<br>
atleast one ring having a conjugated pi- electron system, containing upto two<br>
conjugated or fused ring systems. Aryl includes carbocyclic aryl, heterocyclic aryl<br>
and biaryl groups, all of which may be optionally substituted. The substituents are<br>
selected from F, Cl, Br, I, N, S, O and straight chain or branched C1-C6<br>
hydrocarbon.<br>
The novel compounds of the invention of general formula I having m as 0<br>
and - COR1 at position 3 are listed in Table 1A and the novel compounds of the<br>
invention of general formula 1 having m as 0 and - COR1 at position 4 are listed in<br>
Table IB. The following compounds suggested are by way of example alone of the<br>
representative compounds of the general formula I as defined above and in no way<br>
restrict the invention:<br>
N,N'-Bis[3 -carbonyl-1 -(2-phenyl-2 -oxoethyl)-pyridiniurn] hydrazine dibromide<br>
(compound 1);<br>
 N,N'-Bis[3-carbonyl-l-(2-ethoxy -2- oxoethyl)pyridinium]hydrazine dibromide<br>
(compound 2);<br>
N,N'-Bis[3 -carbonyl-1 -(2-(2,4-dichloropheny l)-2-oxoethyl)p\ridinium]hydrazine<br>
dibromide (compound 3);<br><br>
1- (2- Ethoxy -2- oxoethyl) -3- (2- (2- p&gt;Tidyl) hydrazinocarbonyl) pyridinium<br>
bromide (compound 4);<br>
1- (2- Thien -2'- yl -2- oxoethyl) -3- (methanesulfonyl hydrazinocarbonyl)<br>
pyridinium bromide (compound 5);<br>
N,N'-Bis[3-carbonyl-l- (2- thien -2'- yl -2- oxoethyl)pyridinium]hydrazine<br>
dibromide (compound 6);<br>
1- (2- Ethoxy -2- oxoethyl) -3- (2- (benzoyjoxy) ethylarninocarbonyl) pyridinium<br>
bromide (compound 7);<br>
1- (2.- (2,4- Dichlorophenyl) -2- oxoethyl) -3- (2-(behzoyloxy)ethylamiiio-carbonyi)<br>
pyridinium bromide (compound 8);<br>
'1- (2- Thien -2'- yl -2- oxoethyl) -3- (2- (2- pyridyl) hydrazinocarbony]) pyridinium<br>
bromide (compound 9);<br>
1- (2- Phenyl -2- oxoethyl) -3- (2- (2- pyridyl)hydrazinocarbonyl) pyridinium<br>
bromide (compound 10);<br>
l-(2-Phenyl-2-oxoethyl)-3-(hydrazinocarbon}l)pyridinium bromide (compound 11);<br>
l-(2- Phenyl -2- oxoethyl) -3- (methanesulfonyl hydrazinocarbonyl) pyridinium<br>
bromide (compound 12);<br>
1- (2- Ethoxy -2- oxoethyl) -3- (methanesulfonyl hydrazinocarbonyl) pyridinium<br>
bromide (compound 13);<br><br>
l-(2-Phenyl-2-oxoethyl) -3- (phenylsulfonylhydrazino carbonyl) pyridinium<br>
bromide (compound 14);<br>
l-(2-Phenyl-2-oxoethyl) -2-chloro-3- (phenylsulfonylhydraziiio carbonyl)<br>
pyridinium bromide (compound 15);<br>
l-(2- Phenyl -2- oxoethyl) -3- (2- (acetoxy)ethyloxy carbonyl) pyridinium bromide<br>
(compound 16);<br>
l-(2-Ethoxy -2- oxoethyl) -3- (2- (benzoyloxv) ethyloxy carbonyl) pyridmiuin<br>
bromide (compound 17);<br>
l-(2- Thien -2'- yl -2- oxoethyl)-4-(2-(benzoyloxy)ethylaminocarbonyl) pyridinium<br>
bromide (compound 18);<br>
l-(2-Ethoxy -2- oxoethyl) -4-(phenylsulfonyl hydrazino carbonyl)<br>
pyridinium bromide (compound 19);<br>
l-(2-Phenylamino-2-oxoethyl)-4- (phenylsulfonyl hydrazino carbonyl) pyridinium<br>
chloride (compound 20);<br>
' l-(2-Ethoxy -2- oxoethyl) -3-(phenylsulfonyl hydrazino carbonyl)<br>
pyridinium bromide (compound 21);<br>
l-(2-(2,4-Dichlorophenyl)-2-oxoethyl)-3-(2(methoxy)ethyloxycarbonyl) pyridinium<br>
bromide (Compound 22);<br>
l-(2-Phenylamino-2-oxoethyl)-3-((benzoyloxy)ethylaminocarbonyl)<br>
pyridinium chloride (compound 23);<br><br>
l-(2-Thien-2'-yl-2-oxoethyl)-3-(phenylaminocarbonyl hydrazinocarbonyl)<br>
pyridinium bromide (compound 24);<br>
l-(2-Phenyl-2-oxoethyl)-3-(2-(acetoxy)ethylaminocarbonyl)<br>
pyridinium bromide (compound 25);<br>
1 -(2-Phenylamino-2-oxoethyl)-3-(phenyl sulfonyl hydrazino carbonyl)<br>
pyridinium chloride (compound 26);<br>
1 -(2-Phenylamino-2-oxoethyl)-3-((4-methylphenyl) sulfonyl hydrazino carbonyl)<br>
pyridinium chloride (compound 27);<br>
l-(2-Phenyl-2-oxoethyl)-3-(2-(benzoyloxy)ethyloxy carbonyl)<br>
pyridinium bromide (compound 28);<br>
l-(2-Thien-2'-yl-oxoethyl)-3-(phenylcarbonyl hydrazino carbonyl)<br>
pyridinium bromide (compound 29);<br>
1 -(2-Ethoxy-2-oxoethyl)-3-((phenylmethyl)sulfonyl hydrazino carbonyl)<br>
pyridinium bromide (compound 30);<br>
1 -(2-Phenyl-2-oxoethyl)-3-((phenylmethyl)sulfonyl hydrazino carbonyl)<br>
pyridinium bromide (compound 31);<br>
N, N' - Bis [3-carbonyl-l-(2-furan-2'-yl-2-oxoethyl) pyridinium ]hydrazme<br>
dibromide. (Compound No: 32);<br>
N,N'-Bis [3-carbonyl-1- (2-thien-2'-yl-2-oxoethyl) pyridinium] hydrazine<br>
dichloride.(Compound No: 33);<br>
l-(2-Thien-2'-yl-2-oxoethyl)-3-((2-(l-oxo-3-cyclohexyl)-propyl)-hydrazino<br>
carbonyl)-pyridinium bromide.( Compound No: 34);<br><br>
l-(2-Phenylamino-2-oxo ethyI)-3-({2-(l-oxo-3-cyclohexyl)-propyl} -hydrazino-<br>
carbonyl}-pyridiniura bromide.(Compound No: 35);<br>
l-(2-Thien-2'-yl-2-oxoethyl)-3-[2-(benzoyloxyethylamino carbonyl]-pyridiniuim<br>
romide (Compound No: 36);<br>
l-(4-Ethoxy-2, 4-dioxobutyl)-3-(2-(benzoxyloxy)ethylamino carbonyl)-pyridinium<br>
chloride. (Compound No: 37);<br>
l-(2',4'-Dichloro-phenyl-2-oxoethyI)-3-(2-methoxyethylaminocarbonyl)-pyridinium<br>
bromide. (Compound No: 38);<br>
N,N'-Bis-[3-carbonyl-1 -(2-cycIopropylamino-2-oxoethyl) pyridinium] hydrazine<br>
dichloride. (Compound No: 39);<br>
l-(2-Cyclopropyamino-2-oxoethyl)-3-(2-methoxyethylaminocarbonyl)-pridinuam<br>
chloride. (Compound No: 40);<br>
 N-N'-Bis [3-carbonyl-l-(2-isopropylamino-2-oxoethyl) pyridinium] hydrazine<br>
dichloride. (Compound No: 41);<br>
1 -(2-Thien-2'yl-2-oxoethyl)-3-(2-(2-chloro-3 -pyridoylhydrazinocarbonyl )-<br>
pyridinium chloride. (Compound No: 42);<br>
l-(2-Isopropylamino-2-oxoethyl)-3-(2-methylsulfonylhydrazinocarbonyl)-<br>
pyridinium chloride. (Compound No: 43);<br>
l-(2-(l-Pyrrolidinyl)-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl)<br>
pyridinium chloride.(Compound No: 44);<br>
l-(2-Thien-2'-yl-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl) pyridinium<br>
chloride. (Compound No: 45);<br>
 N,N-Bis[3-carbonyl- l-(2-hydroxy-2-oxoethyl)pyridinium]hydrazine dichloride<br>
(Compound No: 46);<br>
l-(2-Thien-2'-yl-2-oxoethyl)-3-((2-methoxy ethyl) amino carbonyl)-5-bromo<br>
pyridinium chloride (Compound No: 47);<br><br><br><br><br><br><br><br><br><br><br><br>
The invention also provides a process for the preparation of novel<br>
compounds of the pyridinium series.<br>
The said process for the preparation of compound 1, comprises, adding a<br>
solution of phenacyl bromide in isopropanol to N,N'-bis-(nicotinyl)hydrazine<br>
dissolved in methanol, refluxing for six hours, cooling, filtering the precipitated<br>
solid, washing the solid with hot ethyl acetate and finally purifying the solid with 20<br>
ml of methanol : ethyl acetate (3 : 1) to yield the desired compound.<br>
Similarly, the other novel compounds of general formula I, are prepared from<br>
properly substituted pyridine derivatives followed by quarteraization with<br>
appropriate reagent by refluxing in alcoholic solvents like, methanol, ethanol,<br>
propanol, etc and high boiling solvents like toluene or xylene etc, for 6-48 hrs. to<br>
give the desired compounds.<br>
The in vitro AGE formation, studied in the laboratory, by incubating<br>
reducing sugar glucose, with protein bovine serum albumin, resulted in browning of<br>
solution and increase in the fluorescence. Fluorescence was used as the criteria to<br>
monitor the increased AGE formation.<br>
Example 1<br>
AGE breaker activity has been confirmed by the screening procedure as<br>
mentioned below:<br>
Materials:<br><br>
Bovine serum albumin (fraction V) (BSA)<br>
Glucose, analytical grade<br>
Phosphate buffered saline (PBS)<br>
Equipment:<br>
Microplate ELISA Reader - Spectramax Plus (Molecular Devices, USA)<br>
Microplate washer, (Bio -Tec Instruments, USA)<br>
pH meter<br>
Methods of experiment: Elisa (Enzyme Linked Immunosorbent Assay)<br>
160 mg/ml of protein, bovine serum albumin, BSA and 1.6M glucose sugar<br>
were dissolved in phosphate buffered saline, PBS. Sodium azide was added at<br>
0.02% concentration as a preservative. The solution was filtered asceptically<br>
through a 0.22 uM filter and kept for aging at 37°C for 16 weeks. After 16 weeks<br>
the solution was dialyzed against PBS, aliquoted and stored at - 20°C.<br>
To determine the AGE breaking activity, 10µg/ml of the 16 weeks AGE-<br>
BSA was incubated with different concentrations of the test compounds at 37°C for<br>
24 hours and AGE breaking activity of the test compounds by ELISA was<br>
determined.<br>
ELISA was performed as follows:<br>
1. Different concentrations of 16 weeks AGE-BSA were coated on a microtitre<br>
plate as standard. Each concentration is coated in triplicates.<br><br>
2.	The test samples were coated on microtitre plate at a concentration of 5 ng. to 20<br>
ng per well in triplicates.<br>
3.	The plate was incubated at 37°C for one hour.<br><br>
4.	After incubation the plate was washed with PBST (PBS with 0.05% Tween 20).<br>
5.	Blocking with 5% skimmed milk in PBS at 37°C for one hour was done.<br>
6.	The plate was washed with PBST.<br>
7.	Primary antibody against AGE-BSA was added and the plate is incubated at<br>
37°C for one hour.<br>
8.	The plate was washed with PBST<br>
9.	Secondary antibody anti rabbit HRPO (Horse-Radish Per Oxidase) conjugate<br>
was added and the plate is incubated at 37°C for one hour.<br>
10.	The plate was washed with PBST.<br>
11.	Colour development with OPD (orthophenylenediamine dihydrochloride) and<br>
hydrogen peroxide was done.<br>
12.	OD (optical density) at (450nm reading - 620nm reading) was measured after<br>
incubation at 37°C for 15 minutes with Microplate ELISA Reader.<br>
The breaker activity of the compounds were determined by the following<br>
formula:<br><br><br>
OD450-620Control= Absorbance of 20ng AGE-BSA after incubation at 37°C for 24<br>
hours without test compound<br>
OD450-620Test= Absorbance of 20ng AGE-BSA after incubation at 37°C for 24<br>
hours with required concentration of test compound<br>
Using specific examples, the % AGE breaking activity was calculated and recorded<br>
in Table 2.<br><br><br><br>
Hence compound 6 has significant AGE breaking activity i.e. a comparatively much<br>
supeR10r potency vis-a-vis PTB.<br>
The following examples give method of preparation of the specific novel<br>
compounds of the invention as given in Table 1. The following compounds<br>
suggested are by way of example alone and in no way restrict the invention.<br>
Example 2<br>
Preparation of N,N'-bis [3-carbonyl-1- (2-phenyl-2-oxoethyl) pyridinium]<br>
hydrazine dibromide (compound 1):<br>
To a boiling solution of N, 2,-bis-(nicotihyl)hydrazine (1.21 g., 0.005 mol.) in<br>
methanol (20 ml.), a solution of phenacyl bromide (1.99 g., 0.01 mol.) in<br>
isopropanol (10 ml.) was added and the reaction mixture was refluxed for 6 hrs.<br>
The reaction mixture was concentrated under vacuum (~10 ml.) and filtered. The<br>
obtained residue was washed with hot ethylacetate and then the isolated solid was<br>
powdered. It was recrystallised from a mixture of methanol and ethylacetate (3:1,<br>
20 ml) to afford a pale yellow solid.<br>
Yield : 60%<br><br>
m.p. : 260 - 262°C (decomp.)<br>
IR(KBr, cm-1) : 1696 and 1680<br>
1H NMR (DMSOd6, 400MHz) δ: 11.65(2H,s), 9.56(2H,s), 9.21-9.16(4H,m), 8.49-<br>
8.45 (2H,m), 8.08-8.05 (4H,d), 7.81-7.77(2H,m), 7.68-7.64 (4H,m), 6.58 (4H,s)<br>
Mass (m/z): 479, 480<br>
According to the above mentioned procedure the following compounds are<br>
synthesized by reacting the corresponding pyridine derivatives with appropriate<br>
reagents by refluxing in methanol, ethanol, propanol, toluene or xylene for 6-48<br>
hrs. to get the desired compounds:<br>
Example 3<br>
N,N'-Bis[3-carbonyl-l- (2- ethoxy -2-oxoethyl) pyridiniuml hydrazine<br>
dibromide (compound 2):<br>
Yield: 47%<br>
m.p. : 180-182°C (decomp.)<br>
IR(KBr, cm"1) : 1744, 1664<br>
1H NMR (DMSOd6, 400MHz) δ: 11.65 (2H,s), 9.62 (2H,s), 9.28-9.26 (2H,d),<br>
9.17-9.15 (2H,d), 8.47-8.44 (2H,m), 5.77 (4H,s), 4.26 (4H,q), 1.27 (6H,t)<br>
Mass (m/z) : 415, 416<br><br>
Example 4<br>
N,N'-Bis[3-carbonyl-l- (2- (2,4- dichlorophenyl) -2- oxoethyl) pyridinium]<br>
hydrazine dibromide (compound 3):<br>
Yield : 24%<br>
m.p. : 225 - 227°C (decomp.)<br>
IR(KBr, cm'1): 1702,1666<br>
1H NMR (DMSOd6, 400 MHz) δ: 11.69 (2H,s), 9.58 (2H,bs), 9.20-9.18 (4H,m);<br>
8.49-8.47 (2H,m), 8.17-8.15 (2H,d), 7.92 (2H,bs), 7.78-7.76 (2H,d), 6.50 (4H,s)<br>
Mass (m/z): 615, 617, 618, 620.<br>
Example 5<br>
1- (2- Ethoxy -2- oxoethyl) -3- (2- (2- pvridyl) hydrazinocarbonyl) pyridinium<br>
bromide (compound 4):<br>
Yield: 16%<br>
m.p. : 210-212°C<br>
IR (KBr, cm-1): 3140, 3005, 1732 and 1690<br>
1H NMR (DMSO6, 400MHz) δ: 9.63 (lH,s), 9.27 (2H,d), 8.49-8.45 (lH,m) 8.13-<br>
8.07 (2H,m), 7.32-7.30 (lH,m), 7.12-7.1 l(lH,m), 5.77 (2H,s), 4.23 (2H,q), 1.25<br>
(3H,t)<br>
Mass (m/z): 301, 302<br><br>
Example 6<br>
1- (2- Thien -2'- yl -2- oxoethyl) -3- (methanesulfonyl hydrazinocarbonyl)<br>
pyridinium bromide (compound 5):<br>
Yield : 30 %<br>
m.p :	199-200 °C<br>
IR (KBr, cm"1): 1714, 1673<br>
1HNMR (DMSOd6, 400 MHz) δ: 11.38 (lH,s), 9.97 (lH,s) 9.51 (lH,s), 9.16<br>
(lH,d), 9.06 - 9.04 (lH,m), 8.43 - 8.39 (lH,m), 8.25 - 8.21 (2H,m), 7.43 - 7.41<br>
(lH,t), 6.45 (2H,s), 3.08 (3H,s).<br>
Mass (m/z) : 340, 341, 342<br>
Example 7<br>
N,N'-Bis[3-earbonyl-l- (2- thien -2'- yl -2- oxoethyl)pyridiniumlhydrazine<br>
dibromide (compound 6):<br>
Yield: 33%<br>
m.p.: 259 - 261°C (decomp.)<br>
IR (KBr, cm"1): 3330, 1702, 1674, 1655 and 1626<br>
1H NMR (DMSOd6 400 MHz) δ: 11.59 (2H,s), 9.50'(2H,s), 9.15-9.08 (4H,m),<br>
8.40-8.36 (2H,m), 8.17-8.14 (4H,m), 7.33(2H,t), 6.42 (4H,s)<br>
Mass (m/z): 491, 492.<br><br>
Example 8<br>
1- (2- Ethoxy -2- oxoethyl) -3- (2- (benzoyloxv) ethylaminocarbonyl)<br>
pyridinium bromide (compound 7);<br>
Yield: 85%<br>
m.p. : 132-134oC<br>
IR (KBr, cm-1): 3210, 3067, 1726, 1687, 1656<br>
1H NMR (DMSOd6, 400 MHz) δ: 9.46 (lH,s), 9.37 (lH,t), 9.11(lH,t), 8.97<br>
(lH,d), 8.33-8.29 (lH,m) 7.95-7.93 (2H,m), 7.63-7.59 (lH,m), 7.49-7.45 (2H,m),<br>
5.65 (2H,s), 4.39 (2H,t), 4.19 (2H,q), 3.70-3.69 (2H,m), 1.20 (3H,t)<br>
Mass (m/z) : 357, 358, 359<br>
Example 9<br>
1- (2- (2,4- Dichlorophenvl) -2- oxoethyl) -3- (2-( benzoyloxykthyl<br>
aminocarbonyl) pyridinium bromide (compound 8):<br>
Yield: 75%<br>
m.p. : 102-104oC<br>
IR(KBr, cm"1): 1703, 1685, 1675<br>
1H NMR (DMSOd6, 400 MHz) δ: 9.41-9.37 (2H,m), 9.03-8.98 (2H,m)8.34-8.30<br>
(lH,m), 8.04 (lH,d), 7.91-7.89 (2H,m), 7.82 (lH,d),7.68-7.65 (lH,m), 7.58-7.55<br>
(lH,m), 7.43 (2H,t), 6.35 (2H,s). 4.36 (2H,t), 3.68-3.64 (2H,m)<br>
Mass (m/z): 457, 458, 459, 460, 461,462<br><br>
Example 10<br>
1- (2- Thien -2'- yl -2- oxoethyl) -3- (2- (2- pyridyl) hydrazinocarbonyl)<br>
pyridinium bromide (compound 9):<br>
Yield: 10%<br>
m.p. : 212-214°C (decomp)<br>
IR(KBr, cm"1): 1685, 1649<br>
1H NMR (DMSOd6, 400 MHz) δ: 11.21 (lH,bs), 9.59 (lH,s), 9.19 (2H,d), 8-44<br>
(lH,t), 8.27-8.24 (2H,m), 8.08 (lH,bs), 7.62 (lH.bs), 7.44 (lH,t), 6.85-6.79<br>
(2H,m), 6.50 (2H,s)<br>
Mass (m/z): 339, 340, 341<br>
Example 11<br>
1- (2- Phenyl -2- oxoethyl) -3- (2- (2- pyridyl) hydrazinocarbonyl) pyridinium<br>
bromide (compound 10):<br>
Yield : 4%<br>
m.p. : 190°C (decomp)<br>
IRCKBr.cm1): 1683, 1670, 1648<br>
1H NMR (DMSOd6, 400 MHz) δ: 11.14 (lH,bs), 9.53 (lH,s), 9.18-9.13 (2H,m),<br>
8.45-8.42 (lH,t), 8.08-8.06 (3H,m), 7.80 (lH,t), 7.67 (2H,t), 7.62-7.55 (lH,m),<br>
6.83-6.76 (2H,m), 6.54 (2H,s)<br>
Mass (m/z) : 333, 334, 335<br><br>
Example 12<br>
l-(2-PhenyI-2-oxoethyl) -3- (hvdrazinocarbonyl) pyridinium bromide<br>
(compound 11).<br>
Yield: 15%<br>
m.p. :215-216°C<br>
IR(KBr, cm"'): 1695, 1680<br>
1HNMR (DMSOd6, 400 MHz) δ: 10.25 (lH,s) 9.65 (lH,s), 9.35 - 9.32 (2H,m),<br>
8.90 - 8.88 (lH,ra) 8.50 - 8.46 (2H,d), 8.21 - 8.17 (lH,m), 8.05 - 8.07 (2H,m),<br>
6.50 (2H,s), 4.45 (2H,s).<br>
Mass(m/z) : 256, 257.<br>
Example 13<br>
1- (2- Phenyl -2- oxoethyl) -3- (methanesulfonyl hvdrazinocarbonyl)<br>
pyridinium bromide (compound 12):<br>
Yield: 35%<br>
m.p.: 227- 228 °C<br>
IR(KBr, cm-1): 1710, 1702<br>
lHNMR (DMSOd6, 400 MHz) δ: 11.30, (lH,s), 9.88 (lH,s), 9.41 (lH,s), 9.06 -<br>
9.05 (lH,d) 8.98 - 8.96 (lH,d), 8.34 - 8.31 (lH,m), 7.97 (2H,d), 7.72 .- 7.69<br>
(lH,t), 7.59 - 7.56 (2H,t), 6.44 (2H,s), 2.99 (3H,s)<br><br>
Mass (m/z): 334, 335<br>
Example 14<br>
l-(2- Ethoxy -2- oxoethyl) -3- (methanesulfonyl hydrazinocarbonyl) pyridinium<br>
bromide (compound 13):<br>
Yield: 38%<br>
m.p: 75- 76 °C<br>
IR(KBr, cm-1): 1739, 1697<br>
1HNMR (DMSOd6, 400 MHz) δ : 11.39 (lH,s), 9.96 (lH,s), 9.56 (lH,s), 9.23<br>
(lH,d), 9.06 (lH,d), 8.40 (lH,t), 5.75 (2H,s), 4.27-4.22 (2H,q), 3.08 (3H,s), 1.26<br>
(3H,t)<br>
Mass (m/z): 301, 302, 303<br>
Example 15<br>
l-(2-Phenyl-2-oxoethyl)-3-(phenylsulforiyIhydrazino carbonyl) pyridinium<br>
bromide (compound 14):<br>
Yield: 28%<br>
m.p: 187-188°C(dec.)<br>
IR(KBr, cm-1): 1700, 1633<br>
1HNMR (DMSOd6, 400 MHz) δ : 11.38 (lH,s), 10.45 (lH,s), 9.33(1 H,s),<br>
9.13 - 9.12 (lH,d), 8.95 (1H, d), 8.38 (lH,t), 8.05 (2H,d), 7.89 (2H,d),<br>
7.80 (lH,t), 7.66 (3H,t), 7.57 (2H,t), 6.50 (2H,s).<br><br>
Mass(m/z) : 396, 397, 398<br>
Example 16<br>
1- (2-Phenyl-2-oxoethvl)-2-chloro-3-(phenyIsuIfonylhydrazino carbonyl)<br>
pyridinium bromide (compound 15):<br>
Yield: 23%<br>
m.p. : 247 - 250°C (decomp)<br>
IR(KBr, cm-1): 1685, 1679,<br>
1HNMR (DMSOd6, 400 MHz) δ : 11.12 (lH,s), 9.49 (lH,s), 9.07 - 9.03(lH,m),<br>
8.44 (1H, t), 8.07 (2H,d), 7.80 (lH,t), 7.67 (2H,t), 7.18 (2H,t), 6.87 (2H,d), 6.77<br>
(lH,t), 6.50 (2H,s).<br>
Mass(m/z) : 430, 431, 432<br>
Example 17<br>
l-(2- Phenyl -2- oxoethyl) -3- (2- (acetoxy) ethyloxy carbonyl) pyridinium<br>
bromide (compound 16);<br>
Yield :	40%<br>
m.p. :	152-153°C<br>
IR(KBr, cm-1) :1737, 1691, 1635<br>
1HNMR (DMSOds, 400 MHz) δ :9.63(lH,s), 9.24(lH,d), 9.12(lH,d),<br>
8.43(lH,t), 8.07(2H,d), 7.80(lH,t), 7.67(2H,t), 6.59(2H,s), 4.62-4.60<br>
(2H,m), 4.39 - 4.37(2Hm), 2.03 (3H,s)<br><br>
Mass(m/z) :328, 329<br>
Example 18<br>
1- (2- Ethoxy -2- oxoethyl) -3- (2- (benzoyloxy) ethyloxycarbonyl) pyridinium<br>
bromide (compound 17):<br>
Yield :	35%<br>
m.p. :	142-143oC<br>
IRCKBr,cm-1) :	1736,1718,1636<br>
1HNMR (DMSOd6, 400 MHz) δ : 9.60(1 H,s), 9.20-9.18(lH,d), 9.04-<br>
9.02(lH,d), 8.33-8.29(lH,m), 7.90-7.88(2H,d), 7.58-7.57(lH,m), 7.46-7.42(2H,m),<br>
5.67(2H,s), 4.71-4.68(2H,m), 4.58-4.56(2H,m), 4.15(2H,q), 1.16(3H,t)<br>
Mass(m/z) :	358,359,360<br>
Example 19<br>
1- (2- Thien -2'- yl -2- oxoethvl)-4-(2-(benzoyloxy)etfavlaminocarbonyl)<br>
pyridinium bromide (compound 18):<br>
m.p. :	210-211°C<br>
IR(KBr cm-1) :	1723,1680,1668<br>
1HNMR (DMSOd6, 400 MHz) δ : 9.52 (lH,t), 9.14 (2H,d), 8.50 (2H,d), 8.25 -<br>
8.21 (2H,m), 8.01 - 7.99 (2H,d), 7.67 (lH,t), 7.55 - 7.51 (2H,m), 7.42 - 7.40<br>
(lH,m), 6.42 (lH,s) 4.47 - 4.45 (2H,t), 3.77 - 3.73 (2H, m).<br>
Mass(m/z) : 395, 396<br><br>
Example 20<br>
l-(2-Ethoxy-2-oxoethyl)-4-(phenvlsutfonyl hydrazino carbonyl) pvridinium<br>
bromide (Compound 19):<br>
Yield: 60%<br>
m.p. : 171 - 173°C.<br>
IR(KBr, cm-1): 1745, 1685, 1645.<br>
1HNMR (DMSOd6, 400 MHz) δ : 11.41 (1H, s), 10.39 (1H, s), 9.10 (2H, d),<br>
8.27 (2H, d), 7.82 - 7.80 (2H, d), 7.60 - 7.57 (1H, t), 7.50 - 7.46 (2H, t), 5.63 (2H,<br>
s), 4.18-4.12 (2H,q), 1.19-1.15 (3H,t).<br>
Mass (m/z) : 364,365, 366<br>
Example 21<br>
1-(2-Phenvlamino-2-oxoethyl)-4-(phenyIsulfonyl hydrazino carbonyl)<br>
pyridinium chloride (Compound 20):<br>
Yield: 10%<br>
m.p. : 225 - 227°C.<br>
IR(KBr, cm-1) : 1693, 1642, 1592<br>
1HNMR(DMSOd6, 400 MHz) δ : 11.55 (1H, s), 10.99 (1H, s), 10.49 (1H, s), 9.20<br>
(2H, d), 8.34 (2H, d), 7.89 (2H,d), 7.73 - 7.64 (1H, t), 7.61 - 7.56 .(4H, m), 7.37 -<br>
7.33 (2H, t), 7.12 - 7.09 (1H, t), 5.73 (2H, s).<br>
Mass (m/z) : 411,412, 413,414<br><br>
Example 22<br>
l-(2-Ethoxy-2-oxoethvl)-3-(phenylsulfonvlhvdrazino carbonyl) pvridinium<br>
bromide (Compound 21):<br>
Yield: 75%<br>
m.p. : 145 - 147 °C.<br>
IRCKBrcm-1) : 1744, 1713, 1633<br>
1HNMR (DMSOds, 400MHz) δ : 11.27(lH,s),10.36 (1H, s), 9.28(lH,s),<br>
9.09(lH,d), 8.83(lH,d),8.27 - 8.24 (lH,m), 7.82 - 7.79 (2H,m), 7.58 (lH,t),<br>
7.48 (2H,t), 5.59 (2H, s), 4.17 -4.12 (2H, q), 1.16(3H,t).<br>
Mass (m/z) : 364, 365, 366<br>
Example 23<br>
l-(2-(2,4-Dichlorophenyl)-2-oxoethvI)-3- (2(methoxy) ethyloxvcarbonyl)<br>
pyridinium bromide (Compound 22):<br>
Yield : 25%<br>
m.p.: 156-158°C.<br>
IR(KBr, cm"1): 1731, 1706, 1640<br>
1HNMR (DMSO dg, 400 MHz) δ : 9.61 (1H, s), 9.20 (1H, d), 9.13 (1H, d),<br>
8.45 - 8.41 (1H, m), 8.15 (1H, d), 7.92(1H, d), 7.78 - 7.76 (1H, m), 6.49<br>
(2H, s), 4.56 - 4,54 (2H, m), 3.72 - 3.69 (2H, q), 3.31 (3H, s).<br>
Mass (m/z) : 368,369, 370, 371<br><br>
Example 24<br>
l-(2-PhenvIamino-2-oxoethvD-3-(2-(benzovloxyl) ethylaminocarbonvl)<br>
pyridinium chloride (Compound 23):<br>
Yield: 70%<br>
m.p. :171-172°C<br>
IR (KBr, cm'1): 1720, 1692, 1668<br>
"HNMR : (DMSOd^ 400 MHz) δ : 11.06 (1HS s), 9.67 (1H, t), 9.59 (1H, s), 9.20<br>
(lH,d), 9.11 (1H, d), 8.36 - 8.32(1 H, m), 8.00 (2H, d), 7.66 - 7.61<br>
(3H, m), 7.51 (2H,1), 7.34 (2H, t), 7.10 (1H, t), 5.77 (2H,s), 4.45 (2H, t),<br>
3.76 - 3.72 (2H,q).<br>
Mass (m/z): 404, 405, 406, 407<br>
Example 25<br>
l-(2-Thien-2-vI-2-oxoethvlV3-(phenvlaminocarbonylhvdrazinocarbonvl)<br>
pyridinium bromide (Compound 24):<br>
Yield : 30%<br>
m.p.: 202 - 204°C.<br>
ER. (KBr, cm'1): 1718, 1673<br>
1HNMR : (DMSOds, 400 MHz) δ : 11.03 (IK s), 9.55 (1H, s), 9.18 (1H, d), 9.10<br>
(1H, d), 9.00 (1H, s);8.57 (lH,s), 8.46 - 8.42 (1H, t), 8.25 - 8.22 (2H, m), 7.47 -<br><br>
7.45 (2H, d), 7.43 - 7.41 (1H, t), 7.29 - 7.25 (2H, t), 7.0 - 6.96 (1H, t), 6.46 (2H,<br>
s).<br>
Mass (m/z): 381, 382, 383<br>
Example 26<br>
i-(2-Phenyl-2-oxoethyl)-3-(2-(acetoxv) ethylaminocarbonyl) pyridinium<br>
bromide (Compound 25):<br>
Yield: 55%<br>
m.p. : 186-188<br>
IR(KBr, cm"1) : 1734, 1697, 1679<br>
]HNMR (DMSOdk, 400 MHz) δ : 9.47(lH,s), 9.36 (lH,t), 9.13-9.05 (2H, m),<br>
8.42 - 8.38 (1H, m), 8.06 (2H, d), 7.80 (1H, t), 7.67 (2H, t), 6.54 (2H, s), 4.18<br>
(2H,t), 3.61 - 3.57 (2H,q), 2.02 (3H,s).<br>
Mass (m/z): 327, 328,329.<br>
Example 27<br>
l-(2-Phenviamino-2-oxoethyl)-3-(phenyl sulfonyl hydrazino carbonyl)<br>
pyridinium chloride (Compound 26):<br>
Yield: 38%<br>
m.p. :232-234°C.<br>
IR (KBr, cm"1): 1689,1636, 1596<br><br>
1HNMR (DMSOds, 400 MHz) δ : 11.30 (1H, s), 10.80 (1H, s), 10.37 (1H, s), 9.29<br>
(1H, s), 9.09 (1H, d), 8.81 (1H, d), 8.25 - 8.21 (1H, t), 7.82 - 7.80 (2H, d), 7.59 -<br>
7.46 (5H, m), 7.28 - 7.24 (2H, t), 7.04 - 7.00 (1H, t), 5.62 (2H,s).<br>
Mass (m/z): 411, 412, 413, 414<br>
Example 28<br>
l-(2-PhenvIamino-2-oxoethvl)-3-((4-niethvlphenyl)suIfonyl hvdrazino<br>
carbonyl) pvridinium chloride (Compound 27):<br>
Yield : 48%<br>
m.p. : 205 - 206°C<br>
IR(KBr, cm"1): 1712, 1681, 1632<br>
1HNMR (DMSOde, 400 MHz) δ : 11.35 (1H, s), 10.86 (1H, s), 10.36 (1H, s), 9.38<br>
(1H, s), 9.17 (1H, d), 8.90 (lH,d), 8.34 - 8.30 (1H, in), 7.78 - (2H,d), 7.59 (2H,<br>
d), 7.37 - 7.33 (4H,m), 7.11 (lH,t), 5.70 (2H,s), 2.36 (3H, s).<br>
Mass (m/z): 425, 426, 427, 428<br>
Example 29<br>
l-(2-Phenyl-2-oxoethvU-3-(2-(benzoyloxy)ethyIoxy carbonyl) pyridinium<br>
bromide (Compound 28):<br>
Yield: 35%<br>
m.p.: 132-134°C.<br>
IR (KBr, cm"1): 1730, 1705, 1690<br><br>
1HNMR (DMSO4, 400 MHz) δ : 9.80 (1H, s), 9.36 (1H, d), 9.30 (1H, d),<br>
8.58 (1H, t), 8.21 (2H, d), 8.12 (2H, d), 7.95 (1H, t), 7.85 - 7.80 (3 H, m),<br>
7.68 (2H, t), 6.71 (2H, s), 4.95 - 4.93 (2H, m), 4.82 - 4.80 (2H, m).<br>
Mass (m/z): 390, 391, 392.<br>
Example 30<br>
t -f2-Thien-2'-vl-2-oxoethvI)-3-(Dhenylca rbonvl hyd razino carbonyl)<br>
pvridinium bromide (Compound 29):<br>
Yield: 45%<br>
m.p. : 80-81 °C<br>
IRCKBrCm1): 1700, 1663, 1631<br>
!HNMR (DMSOdg, 400MHz) δ : 11.49 (1H, s), 10.95 (1H, s), 9.67 (1H, s),<br>
9.34 (1H, d), 9.27 (1H, d), 8.52 ~ 8.48 (1H, m), 8.29 - 8.28 (2H, m), 8.00<br>
(2H, d), 7.68 (1H, t), 7.59 (2H, t), 7.46 (1H, t), 6.63 (2H,s)<br>
Mass (m/z): 366,367, 368,369<br>
Example 31<br>
l-(2-Ethoxy-2-oxoethvl)-3-((phenylmethvl)sulfonvlhydrazino carbonyl)<br>
pyridinium bromide (Compound 30):<br>
Yield: 50%<br>
m.p. : 147-148°C<br>
ffi. (KBr, cm"1) : 1749, 1698, 1640<br><br>
1HNMR (DMSOds, 400 MHz) δ : 11.57 (1H, s), 10.21 (lH,s), 9.75 (lH,s),<br>
9.38 (1H, d), 9.24 (1H, d), 8.59 - 8.56(1H, m), 7.67 - 7.65 (2H, m), 7.58 -<br>
7.52 (3H, m), 5.90 (2H, s), 4.68 (2H, s), 4.45 - 4.39 (2H, q), 1.43 (3H, t).<br>
Mass (m/z): 377, 378, 379<br>
Example 32<br>
l-(2-Phenyl-2-oxoethyl)-3-((phenyImethyl)sulfonylhvdrazino<br>
carbonyQpyridinium bromide (Compound 31):<br>
Yield : 80%<br>
m.p. : 205-207° C<br>
ffi. (KBr, Cm"1) : 1687,1637<br>
IHNMR (DMSOds, 400 MHz) δ : 11.59 (lH,s), 10.20 (lH,s), 9.71 (lH,s),<br>
9.33 (1H, d), 9.27 (1H, d), 8.62 - 8.59(1H, m), 8.25 - 8.23 (2H, d),<br>
7.99 -7.95 (1H, t), 7.86 - 7.82 (2H, t), 7.67 - 7.65 (2H, m), 7.57 - 7.52<br>
(3H, m),6.72 (2H, s), 4.69 (2H, s).<br>
Mass (m/z): 410,411, 412, 413<br>
Example 33<br>
N, N' - Bis r3-carbonyl-l-(2-furan-2'-vI-2-oxoethvn pyridinium lhvdrazine<br>
dibromide. (Compound No: 32)<br>
Yield :23%<br><br>
Yield	15%<br>
m.p.	217 219 °C(dec)<br>
IR (KBr, cm"1)	:3190, 1708, 1667 and 1404<br>
1H NMR (DMSO d6, 400 MHz) 8: 11.07 (lH.s), 10.22 (lH,s), 9.51 (IH.s), 9.16 -<br>
9.15 (IH.d), 9.06 - 9.04 (IH.d), X 42 - 8.40 (lH,m). 8.25 - 8.21 (2H,m), 7.43 - 7.40<br>
(lH.m), 6 44 (7ll,s), 2.25 -2.22 (2H.t), 1.72- 1,60 (5H,m), 1.49- 1.43(2H,q).<br>
1.24 - 1 10 (IHjn), 0.9-0 85 (211.ml<br>
Mass (in /)	40-J. 101,402 and 403<br>
Example 36<br>
l-(2-Phenvlamino-2-oxo cthvl)-3-( |2-(l-oxo-3-cvclohexyl)-nroi)vli -hvdni/ino-<br>
carbonvll-pvridinium bromide.K ortuMiund No: 35):<br>
Yield	: 25%<br>
m.p	: 234-236 °C (dec)<br>
IR (KBr, cm!)	: 1689, 1652 and 1625<br>
'11 NMR (DMSO 4,400 MHz) δ: 11.11 (lH,s), 10.95 (IH,s), 10.23 (lH,s), 9.56<br>
(IH.s), 9.23 - 9.21 (IH.d), 9.06 - 9.04 (IH,d), 8.38-8.35 (IH,m). 7.62 - 7.60<br>
(2H,d), 7.37 - 7.33 (2H,t), 7.12 - 7.C9 (lH,t), 5.75 (2H,s), 2.25 - 2.22 (2H,t), 1.72 -<br>
I.60(5H,n) 1.49- 1.43 (2H,m), 1.25- 1.10 (4H,m), 0.91 - 0.83 (2H,m)<br>
Mass(m//)	:409, 410, 411 and 412<br><br>
Example 37<br>
l-(2-Thien-2'-vI-2-oxoethyl)-3-[2-(benzovloxy)ethvlaminocarbonyl1-<br>
pyridinium bromide (Compound No:36);<br>
Yield	: 40%<br>
m.p.	: 125-127°C<br>
IR(KBr, cm-1)	:1710 and 1675<br>
1H NMR (DMSO6, 400 MHz) δ: 9.48 (1 H,s), 9.43 - 9.41 (1 H,t), 9.12 - 9.11<br>
(lH,d), 9.05 - 9.02 (lH,d), 8.40 - 8.36 (1 H,m), 8.25 - 8.20 (2H,m), 8.00 - 7.98<br>
(2H,m), 7.68 - 7.64 (lH,m), 7.54-750 (2H,m), 7.42 - 7.40 (lH,m), 6.43 (2H,s),<br>
4.46-4.43 (2H,t), 3.77-3.73 (2H,q)<br>
Mass (m/z)	:395, 396, 397 and 398<br>
Example 38<br>
l-(4-Ethoxv-2, 4-dioxobutyl)-3-(2-(benzoxvloxv)ethvIamino carbonvl)-<br>
pyridinium chloride. (Compound No: 37);<br>
Yield	: 35%<br>
m.p.	: 147-149°C<br>
IR (KBr, cm4)	:1743, 1720, 1680 and 1627<br>
1H NMR (DMSOd6, 400 MHz) δ: 9.62 - 9.59 (lH,t), 9.32 - 9.29 (lH,s), 9.05 -<br>
9.03 (lH,d), 8.93 - 8.90 (lH,d), 8.27 - 8.24 (lH,m), 7.92 - 7.89 (2H,d), 7.59 - 7.55<br><br>
(lH,m), 7.45 - 7.41 (2H,m), 5.82 (2H,s), 4.37-4.34 (2H,t), 4.08-4.03 (2H,q), 3.80<br>
(2H,s), 3.67-3.63 (2H,q), 1.15-1.11 (3H,t),<br>
Mass (m/z)	:399, 400 and 401<br>
Example 39<br>
l-(2'4'-DichIoro-phenyl-2-oxoethyl)-3-(2-methoxyethyl aminocarbonyl)-<br>
pyridinium bromide. (Compound No: 38);<br>
Yield	: 70%<br>
m.p.	: 93-95 °C<br>
BR. (KBr, cm"1)	:1704, 1664 and 1636<br>
1H NMR (DMSO d6, 400 MHz) δ: 9.48 (lH,s), 9.29 (lH,bs), 9.11 - 9.08 (2H,m),<br>
8.41 - 8.38 (lH,m), 8.15 - 8.13 (lH,d), 7.92 - 7.91 (lH,t), 7.78 - 7.75 (lH,m), 6.44<br>
(2Hs,) 3.52 (2H,bs), 3.51 (2H,bs); 3.28 (3H,s)<br>
Mass (m/z)	:367,368,369 and 370<br>
Example 40<br>
N,N'-Bis-[3-carbonyl-l-(2-cvclopropylamino-2-oxoethvl) pyridiniuml<br>
hydrazine dichloride. (Compound No: 39);<br>
Yield	: 40%<br>
m.p.	: 228-230 °C<br><br>
IR (KBr cm"1)	:1675,1636 and 1298<br>
1H NMR (DMSO 4, 400 MHz) S: 11.85 (2H,s), 9.59 (2H,s), 9.25 - 9.19 (4H,m),<br>
. 9.00 - 8.99 (2H,d), 8.39 - 8.36 (2H,m), 5.53 (4H,s), 2.73 - 2.66 (2H,m), 0.78 - 0.62<br>
(4H,m), 0.53 - 0.49 (4H,m)<br>
Mass (m/z) 437,438 and 439<br>
Example 41<br>
l-(2-CvcIopropvlamino-2-oxoethyl)-3-(2-methoxvethvIaminocarbonyl)-<br>
pyridinium chloride. (Compound No: 40);<br>
Yield	: 10%<br>
m.p.	: 122-124 °C<br>
IR(KBr, cm-1)	:1661, 1633, 1549 and 1121<br>
1H NMR (DMSO d6, 400 MHz) δ: 9.40 (lH,s), 9.08 - 9.02 (2H,m), 8.28 - 8.25<br>
(lH,m), 5.53 (2H,s), 3.66 - 3.61 (4H,m), 3.39 (3H,s), 2.78 - 2.74 (lH,m), 0.80 -<br>
0.75 (2H,m), 0.64 - 0.61 (2H,m)<br>
Mass (m/z)	:278, 279 and 280<br>
Example 42<br>
N-N'-Bis [3-carbonyl-l-(2-isopropvlamino-2-oxoethvl) pvridiniuml hydrazine<br>
dichloride. (Compound No: 41):<br><br>
Yield	: 35%<br>
m.p.	: 114-116 °C (dec)<br>
IR (KBr, cm-1)	:1707, 1668 and 1637<br>
1H NMR (OMSO d6: 400 MHz) δ: 11.84 (2H,s), 9.59 (2II,s), 9.21-9.18 (4H,m),<br>
8.74-8.72 (2H,d), 8.39 - 8.35 (2H,m), 5.53 (4H,s), 3.92 - 3.84 (2H,m), 1.14-1.02<br>
(12H,d)<br>
Mass(m/z)	: 441, 442 and 443<br>
Example 43<br>
l-(2-Thien-2 yl-2-oxoethyl-3-(2-(2-chloro-3-pyridovlhydrazinocarbonyl)-<br>
pyridinium chloride. (Compound No: 42);<br>
Yield	: 56%<br>
m.p.	: 233-235 °C<br>
IR (KBr, cm -1)	: 1680, 1637, 1404 and 1293<br>
1H NMR (DMSO d6, 400 MHz) δ: 11.62 (lH,s), 11.05 (lH,s), 9.62 (lH,s), 9.24 -<br>
9.23 (1 H,d), 9.18-9.16(1 H,d), 8.58 - 8.56 (1 H,m), 8.46 - 8.43 (1 H,m), 8.26 - 8.24<br>
(2H,m), 8.02 - 8.00 (lH.tn), 7.61-7.58 (lH,m), 7.43 - 7.41 (lH,m), 6.51 (2H,s)<br>
Mass (m/z)	:401, 402, 403, 404 and 405<br><br>
Example 44<br>
l-(2-Isopropvlamino-2-oxoetbyI)-3-(2-methylsulfonylhydrazinocarbonyl)-<br>
pyridinium chloride. (Compound No: 43);<br>
Yield	: 10%<br>
m.p.	: 227 - 229 °C<br>
IR(KBr, cm-1)	:1691, 1670, 1566 and 1330<br>
1HNMR (DMSO d6, 400 MHz) δ: 11.55 (lH,s), 9.94 (lH,s), 9.52 (lH,s), 9.16 -<br>
9.14 (lH,m), 9.09 - 9.07 (lH,m), 8.72 - 8.70 (lH,m), 8.34 - 8.30 (lH,m)&gt; 5.50<br>
(2H,s), 3.89 - 3.84 (lH,m), 3.11 (3H.s), 1.13 - 1.12 (6H,d)<br>
Mass(m/z)	:315,316 and 317<br>
Example 45<br>
l-(2-(l-Pyrrolidinvl)-2-oxoethvl)-3-(methanesulfonvI hydrazino carbonyl)<br>
pyridinium chloride (Compound No; 44);<br>
Yield	:21.00%<br>
m.p.	:205-207°C<br>
IR (KBr, cm-1)	: 1699, 1646 and 1589<br><br>
1HNMR :(DMSO d6, 400 MHz) 5 : 11.50 (1H, s), 9.94 (1H, s), 9.46 (1H, s), 9.11<br>
- 9.06 (2H, m), 8.36 - 8.33 (1H, t), 5.75 (2H, s), 3.55 - 3.48 (3H, m), 3.10 (3H, s),<br>
2.00 - 1.95 (2H, m), 1.87-1.81 (2H, m)<br>
Mass (m/z)	:327, 328, 329 and 330<br>
Example 46<br>
l-(2-Thien-2'-vl-2-oxoethvI)-3-(methanesulfonyl	hvdrazino	carbonvl)<br>
pyridinium chloride (Compound No: 45);<br>
Yield	:31.00%<br>
m.p.	:215-217°C<br>
' 1R (KBr, cm-1)	:1685, 1666 and 1635<br>
1HNMR :(DMSO d*, 400 MHZ) 8: 11.49, (1H, s), 9.96 (1H, s), 9.55 (1H, s), 9.18<br>
(1H, d), 9.10 (1H, d), 8.43 - 8.39 (1H, t), 8.25 - 8.22 (2H, m), 7.42 (1H, t) 6.47<br>
(2H, s), 3.09 (3H, s).<br>
Mass (m/z)	:340, 341, 342 and 343<br>
Example 47<br>
N,N'-Bis[3-carboDvl-l-(2-hvdroxv-2-oxoethynpyridinium1hydrazine dichloride<br>
(Compound No: 46);<br>
Yield	: 43.00%<br><br>
m.p.	:235 - 240°C (d)<br>
IR (KBr, cm"1)	: 1743, 1700 and 1672<br>
1HNMR (DMSO d*, 400 MHz) δ: 11.89 (2H, s), 9.69 (2H, s), 9.31 - 9.29 (2 H,<br>
d), 9.25 - 9.23 (2H, d), 8.43 - 8.39 (2H, t) 5.70 (4H, s)<br>
Mass(m/z)	:360,361,362<br>
Example 48<br>
l-(2-Thien-2'-vl-2-oxoethyI)-3-((2-methoxy ethyl) amino carbonvD-S-bromo<br>
pyridinium chloride (Compound No: 47);<br>
Yield	:31.00%<br>
m.p.	:180-182°C<br>
IR (KBr, cm"1)	: 1661 and 1620<br>
1HNMR (DMSO dg, 400 MH2) δ : 9.58 - 9.54 (2H, d), 9.43 - 9.39 (2H, d), 8.25 -<br>
8.21 (2H, m), 7.41 (1H, t), 6.43 (2H, s), 3.51 (4H, m), 3.29 (3H, s).<br>
Mass(m/z)	: 384, 385, 386, 387 and 388<br>
Example 49<br>
l-(2-Thien-2'-vl-2-oxoethyl)-3-fl-oxo-l-(2-methoxvcarbonvl)pyridvn<br>
hydrazino pyridinium chloride (Compound No: 48);<br>
Yield	:30.00%<br>
m.p.	:222 - 225°C<br><br>
IR (KBr, cm"1)	: 1726, 1708 and 1662<br>
1HNMRCDMSOd^OOMH^S: 11.47 (lH,s), 11.23 (1H, s), 9.58 (1H, s), 9.22<br>
- 9.15 (3H, m), 8.56 - 8.53 (1H, d), 8.46 - 8.43 (1H, t) 8.25 - 8.21 (3H, m), 7.42<br>
(1H, t), 6.49 (2H, s), 3.95 (3H, s)<br>
Mass (m/z)	:425, 426 and 427<br>
Pharmaceutical compositions may be prepared with a pharmaceutically<br>
effective quantity of compounds of general formula 1, individually or in<br>
combination. The following pharmaceutical formulations suggested are by way of<br>
example alone and in no way restrict the forms in which they can be used.<br>
Oral formulations may be administered as solid dosage forms for example<br>
pellets, powders, sachets or discreet units such as tablets or capsules and like.<br>
Other orally administered pharmaceutical preparations include monophasic and<br>
biphasic liquid dosage forms either in ready to use form or forms suitable for<br>
reconstirution such as mixtures, s)Tups, suspensions or emulsions. The preparations<br>
in addition may contain diluents, dispersing agents, buffers, stabilizers, solubilizers,<br>
surfactants, preservatives, chelating agents and/ or other pharmaceutical additives<br>
as are used. Aqueous or non aqueous vehicle or their combination may be used and<br><br>
if desired may contain suitable sweetener, flavoring agent or similar substances. In<br>
case of suspension or emulsion a suitable thickening agent or suspending agent or<br>
emulsifying agent may be present in addition. Alternatively, the compounds may be<br>
administered as such in their pure form unassociated with other additives for<br>
example as capsules or sachets. It may also be administered with a vehicle.<br>
Pharmaceutical preparations can have a slow, delayed or controlled release of<br>
active ingredients as is provided by a matrix or diffusion controlled system.<br>
When the present invention or its salts or suitable complexes is presented as<br>
a discreet unit dosage form like tablet, it may contain in addition medically inert<br>
excipients as are used in the art. Diluents such as starch, lactose, dicalcfum<br>
phosphate, talc, magnesium stearate, polymeric substances like methyl cellulose,<br>
fatty acids and derivatives, sodium starch glycollate, etc. may also be used.<br>
Example 50<br>
Preparation of oral dosage form;<br>
A typical tablet has the following composition:<br>
Active ingredient of formula I	as given above<br>
Lactose	135 mg<br>
Starch	76 mg<br>
Polyvinyl pyrolidone (K-30)	2 mg<br><br>
Talc	1.5 mg<br>
Magnesium Stearate	1.0 mg<br>
Parenteral Formulations<br>
For parenteral administration, the compounds or their salts or suitable<br>
complexes thereof may be present in a sterile vehicle which may be an aqueous or<br>
non aqueous vehicle or a combination thereof. The examples of vehicles are water,<br>
ethyl oleate, oils and derivatives of polyols, glycols and their derivatives. It may<br>
contain additives common in injectable preparations like stabilizers, solubilizers,<br>
pH modifiers, buffers, antioxidants, cosolvents, complexing agents, tonicity<br>
modifiers, etc.<br>
Some suitable additives are for example tartrate, citrate or similar buffers,<br>
alcohol, sodium chloride, dextrose and high molecular weight polymers. Another<br>
alternative is sterile powder reconstirution. The compound may be administered in<br>
the form of injection for more than once daily administration, or intravenous<br>
infusion/ drip or suitable depot preparation.<br>
Example 51<br>
Preparation suitable for parenteral administration has the following<br>
composition:<br>
Active ingredient of formula I	as given above<br>
Polyethylene glycol (400)	0.75 ml<br><br>
Sodium metabisulphite	0.01 %<br>
Isotonic saline/ WFI	q.s.<br>
For the derraatological application and for the discoloration of teeth, the<br>
recommended formulations are lotions, oral rinse and. toothpaste containing<br>
appropriate amount of the compounds of the general formula I.<br>
The above examples are presented by way of illustration alone and in no way<br>
limit the scope of the invention.	t.<br><br>
WE CLAIM :<br>
1. A compound selected from the group consisting of the following<br>
compounds<br>
(a) l -(2-phcnylammo-2-oxoethyl)- 1-(phenylsulfonyI hydrazino carbonyl)<br>
pyridinium chloride and pharmaceutically acceptable salts thereof,<br>
(b)	l-(2-(2,4-dichlorophcnyl)-2-oxocthyl)-3- (2(mcthoxy) ethyloxycarbonyl)<br>
pyridirdium bromide and pharmaceutically acceptable salts thereof,<br>
(c)	l-(2-phenylamino-2-oxoethyl)-3-((benzoyloxy) ethylaminocubonyl)<br>
pyridinium chloride and pharmaceutically acceptable salts thereof,<br>
(J) l-(2-:!:icn-2'-yl-2-cxoetliyl)-3-(phcnyhniinocarbonyI hydrazinocarbonyl)<br>
pyndmiun bromide and phannaceuUcally acceptable sails thereof,<br>
(L») l-(2-phenyl-2-oxocthyl}-3-(2-(accto\'y) cthylaminocarbonyl) nyridiniuin<br>
bromide and phanr.accutically acceptable salts thereof,<br>
(S) l-(2-pliccyIanuuo-2-oxocthyl&gt;3-(phcr.yl sulfonyl hydrazino carbonyl)<br>
pyridiniu.71 chloride and plwrmaccuticaUy acceptable salts thereof,<br>
(3) l-(2-plicnylauiiiiu-2-oxoc,Jiyl)-3-{(4-iiictliylphcnyl)suJfoiiyl hydrazino<br>
carbonyl) pyridinium chloride and pharmacculicaJIy acceptable salts thereof,<br>
(h) l-(2-phenyl-2-oxocthyl)-3-(2-(bcnzoyloxy)cthyloxy carbonyl) pyridinium<br>
bromide and pharmaceutically acceptable salts thereof,<br>
(1) l-(2-thien-2,-yl-2-oxoethyl)-3-(phcnylcarbonyl hydrazino carbonyl)<br>
pyndinium bromide and pharmaceutically acceptable salts thereof,<br>
(j) l-(2-c:hoxy-2-cxocthyl)-3-((pharmaceutically)suIfonyl liydra/ino carbonyl)<br>
pyridinium bromide and pharmaceutically acceptable sails thereof,<br>
(lyl-(.2-phenyl-2-(exocthyl)-3-((phenylmcthyl)sulfonyl hydrazino carbony))<br><br>
pyridiomm bromide and pharmaceutically acceptable salts thereof.<br>
(c ) N, N' - bis [3-carbonyl-l-(2-furan-2'-yl-2-oxoethyl) pyridinium ]hydrazine<br>
dibromide,<br>
(m) N,N'- bis [3-carbonyl -1- (2-thien-2'-yl-2-oxoethyI) pyridinium] hydrazine <br>
dichloride.<br>
(n ) N,N'-bis-[3-carbonyl-l-(2-cyc]opropylaraino-2-oxoethyl)pyridininum]<br>
hydrazine dichloride,<br>
( o ) l-(2',4'-dichioro-phenyl-2-oxoethyl)-3-(2-methoxyethyl aminocarbonyl)-<br>
pyridinium bromide,<br>
( P ) l-(2-thien-2'-yl-2-oxoethyl)-3-((2-methoxy ethyl) amino carbonyl)-5-bromo<br>
pyridinium chloride,<br>
(q,) 1 -(2-thien-2'-yl-2-oxoethyI)-3-(methanesulfonyl hydrazino carbonyl) pyridinium<br>
chloride,<br>
( r) l-(2-thien-2yl-2-oxoethyl)-3-)2-(2-chloro-3-pyridoymydrazinocarbonyl)-<br>
pyridinium chloride,<br>
(' s ) 1 -(2-cyclopropylammo-2-oxoethyl)-3-(2-memoxyemyIaminocarbonyl)-<br>
pyridinium chloride,<br>
(t) l-(2-isopropyIarnino-2-oxoethyl)-3-(2-mediylsulfonymydtazinocarbonyl)-<br>
pyridinium chloride,<br>
(u) l-(2-phen)lamino-2-oxo ethyl)-3-({2-(l-oxo-3-cyclohexyl)-propyl} -<br>
hydrazino-carbonyl} -pyridinium bromide,<br>
( Y). l-(2-uhien-2'-yl-2-oxoemyl)-3-[2-(benzoyIoxy)emylamino carbonyl]-<br>
pyridinium bromide,<br>
(w) l-(4-ethoxy-2,4-dioxobu(yl)-3-(2-(benzoxyloxy)ethylamino carbonyl)-<br>
pyridinium chloride and<br>
(x ) l-(2-tluen-2,-yl-2-oxoethyl)-3-[l-oxo-l-(2-methoxy carboiryl)pyridyl]<br>
hydrazino pyridiniuin chloride.<br>
2. A process for the preparation of the compound as claimed in claim 1, which<br>
comprises preparing a substituted pyridine, according to the desired end<br>
product followed by quaternizing of the substituted pyridine, with an<br>
appropriate reagent by refluxing in an alcoholic and/or high boiling solvent for<br>
6-48 hrs. to give the desired compound.<br><br>
3.	A pharmaceutical composition for treatment of diabetic complications and aging<br>
related diseases which comprises a pharmaceutically effective amount of one or<br>
more compounds, as defined in claim 1, or pharmaceutically acceptable salt(s)<br>
thereof in admixture with a pharmaceutically acceptable carrier, diluent,<br>
solvent or excepient.<br>
4.	The pharmaceutical composition as claimed in-claim 3, in the form of an oral<br>
formulation.<br>
5.	The pharmaceutical composition as claimed in claim 4, wherein said<br>
pharmaceutically acceptable carrier is selected from group consisting of starch,<br>
lactose, polyvinyl pyrolidone (K-30), talc and magnesium stearate.<br>
6.	The pharmaceutical composition as claimed in claim 3, in the form of a<br>
parenteral formulation.<br>
7.	A method for fee preparation of a parenteral formulation as claimed in claim 6,<br>
which comprises dissolving one or more compounds represented by general<br>
formula (I), as defined in claim 1, in polyethylene glycol 400 and diluting the<br>
solution so obtained, with an isotonic solution or water to a desired concentration.<br>
8.Pharmaceutical composition as claimed in claim 5., in the form of a lotion, oral<br>
rinse and toothpaste.<br><br><br>
The invention discloses novel compounds of the pyridinium series useful for the<br>
management of diabetes and aging-related vascular complications, including<br>
kidney disease, nerve damage, atherosclerosis, retinopathy, dermatological<br>
disorders and discoloration of teeth, by breaking preformed AGE, of the general<br>
formula I, or pharmaceutically acceptable salts thereof,</td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LUFCU1RSQUNUIC4xMS5wZGY=" target="_blank" style="word-wrap:break-word;">828-CAL-1999-ABSTRACT .11.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LUFCU1RSQUNULnBkZg==" target="_blank" style="word-wrap:break-word;">828-CAL-1999-ABSTRACT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LUFNQU5ERUQgQ0xBSU1TLnBkZg==" target="_blank" style="word-wrap:break-word;">828-CAL-1999-AMANDED CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LUFTU0lHTk1FTlQgMS4xLnBkZg==" target="_blank" style="word-wrap:break-word;">828-CAL-1999-ASSIGNMENT 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LUFTU0lHTk1FTlQuMS4zLnBkZg==" target="_blank" style="word-wrap:break-word;">828-CAL-1999-ASSIGNMENT.1.3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LUFTU0lHTk1FTlQucGRm" target="_blank" style="word-wrap:break-word;">828-CAL-1999-ASSIGNMENT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LUNMQUlNUy5wZGY=" target="_blank" style="word-wrap:break-word;">828-CAL-1999-CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LUNPUlJFU1BPTkRFTkNFLjEuMy5wZGY=" target="_blank" style="word-wrap:break-word;">828-CAL-1999-CORRESPONDENCE.1.3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LUNPUlJFU1BPTkRFTkNFLnBkZg==" target="_blank" style="word-wrap:break-word;">828-CAL-1999-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LURFU0NSSVBUSU9OIChDT01QTEVURSkgIDEuMS5wZGY=" target="_blank" style="word-wrap:break-word;">828-CAL-1999-DESCRIPTION (COMPLETE)  1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LURFU0NSSVBUSU9OIChDT01QTEVURSkucGRm" target="_blank" style="word-wrap:break-word;">828-CAL-1999-DESCRIPTION (COMPLETE).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LUVYQU1JTkFUSU9OIFJFUE9SVCBSRVBMWSBSRUNJRVZFRC5wZGY=" target="_blank" style="word-wrap:break-word;">828-CAL-1999-EXAMINATION REPORT REPLY RECIEVED.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LUVYQU1JTkFUSU9OIFJFUE9SVC4xLjMucGRm" target="_blank" style="word-wrap:break-word;">828-CAL-1999-EXAMINATION REPORT.1.3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LUVYQU1JTkFUSU9OIFJFUE9SVC5wZGY=" target="_blank" style="word-wrap:break-word;">828-CAL-1999-EXAMINATION REPORT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LUZPUk0gMSAgIDIuMS5wZGY=" target="_blank" style="word-wrap:break-word;">828-CAL-1999-FORM 1   2.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LUZPUk0gMS5wZGY=" target="_blank" style="word-wrap:break-word;">828-CAL-1999-FORM 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LUZPUk0gMTMuMS4zLnBkZg==" target="_blank" style="word-wrap:break-word;">828-CAL-1999-FORM 13.1.3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LUZPUk0gMTMucGRm" target="_blank" style="word-wrap:break-word;">828-CAL-1999-FORM 13.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LUZPUk0gMTguMS4zLnBkZg==" target="_blank" style="word-wrap:break-word;">828-CAL-1999-FORM 18.1.3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LUZPUk0gMTgucGRm" target="_blank" style="word-wrap:break-word;">828-CAL-1999-FORM 18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LUZPUk0gMiAgMS4xLnBkZg==" target="_blank" style="word-wrap:break-word;">828-CAL-1999-FORM 2  1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LUZPUk0gMi5wZGY=" target="_blank" style="word-wrap:break-word;">828-CAL-1999-FORM 2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LUZPUk0gMyAgMS4xLnBkZg==" target="_blank" style="word-wrap:break-word;">828-CAL-1999-FORM 3  1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LUZPUk0gMy4xLjMucGRm" target="_blank" style="word-wrap:break-word;">828-CAL-1999-FORM 3.1.3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LUZPUk0gMy5wZGY=" target="_blank" style="word-wrap:break-word;">828-CAL-1999-FORM 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LUZPUk0gNC4xLjMucGRm" target="_blank" style="word-wrap:break-word;">828-CAL-1999-FORM 4.1.3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LUZPUk0gNC5wZGY=" target="_blank" style="word-wrap:break-word;">828-CAL-1999-FORM 4.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LUZPUk0gNS4xLjMucGRm" target="_blank" style="word-wrap:break-word;">828-CAL-1999-FORM 5.1.3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LUZPUk0gNS5wZGY=" target="_blank" style="word-wrap:break-word;">828-CAL-1999-FORM 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LUZPUk0tMjcucGRm" target="_blank" style="word-wrap:break-word;">828-CAL-1999-FORM-27.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LUdQQS4xLjMucGRm" target="_blank" style="word-wrap:break-word;">828-CAL-1999-GPA.1.3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LUdQQS5wZGY=" target="_blank" style="word-wrap:break-word;">828-CAL-1999-GPA.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LUdSQU5URUQtQUJTVFJBQ1QucGRm" target="_blank" style="word-wrap:break-word;">828-CAL-1999-GRANTED-ABSTRACT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LUdSQU5URUQtQ0xBSU1TLnBkZg==" target="_blank" style="word-wrap:break-word;">828-CAL-1999-GRANTED-CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LUdSQU5URUQtREVTQ1JJUFRJT04gKENPTVBMRVRFKS5wZGYucGRm" target="_blank" style="word-wrap:break-word;">828-CAL-1999-GRANTED-DESCRIPTION (COMPLETE).pdf.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LUdSQU5URUQtRk9STSAxLnBkZg==" target="_blank" style="word-wrap:break-word;">828-CAL-1999-GRANTED-FORM 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LUdSQU5URUQtRk9STSAyLnBkZg==" target="_blank" style="word-wrap:break-word;">828-CAL-1999-GRANTED-FORM 2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LUdSQU5URUQtU1BFQ0lGSUNBVElPTi5wZGYgLnBkZg==" target="_blank" style="word-wrap:break-word;">828-CAL-1999-GRANTED-SPECIFICATION.pdf .pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LU9USEVSUyBET0NVTUVOVFMucGRm" target="_blank" style="word-wrap:break-word;">828-CAL-1999-OTHERS DOCUMENTS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LU9USEVSUy4xLjMucGRm" target="_blank" style="word-wrap:break-word;">828-CAL-1999-OTHERS.1.3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LU9USEVSUy5wZGY=" target="_blank" style="word-wrap:break-word;">828-CAL-1999-OTHERS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LVBBLnBkZg==" target="_blank" style="word-wrap:break-word;">828-CAL-1999-PA.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LVJFUExZIFRPIEVYQU1JTkFUSU9OIFJFUE9SVC4xLjMucGRm" target="_blank" style="word-wrap:break-word;">828-CAL-1999-REPLY TO EXAMINATION REPORT.1.3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LVJFUExZIFRPIEVYQU1JTkFUSU9OIFJFUE9SVC5wZGY=" target="_blank" style="word-wrap:break-word;">828-CAL-1999-REPLY TO EXAMINATION REPORT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=ODI4LUNBTC0xOTk5LVNQRUNJRklDQVRJT04ucGRm" target="_blank" style="word-wrap:break-word;">828-CAL-1999-SPECIFICATION.pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="250727-process-for-the-preparation-of-storage-stable-multiple-emulsions.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="250729-power-unit.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>250728</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>828/CAL/1999</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>04/2012</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>27-Jan-2012</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>23-Jan-2012</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>06-Oct-1999</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>TORRENT PHARMACEUTICALS LTD.</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>CENTRAL PLAZA, 1ST FLOOR, ROOM # - 106, 2/6, SARAT BOSE ROAD CALCUTTA - 700 020, WEST BENGAL, INDIA, AND ALSO AT TORRENT HOUSE, NEAR DINESH HALL, OFF. ASHRAM ROAD, AHMEDABAD - 380 009, GUJRAT, INDIA</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>SANKARANARAYANAN ALANGUDI</td>
											<td>B-7, SWASTIK PARK, PREMSCHANDNAGAR ROAD, BODAKDEV, AHMEDABAD - 380054</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>C07D 213/80</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>N/A</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td></td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td></td>
									<td></td>
								    <td>NA</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/250728-a-compound-of-pyridinium-series by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 14:16:42 GMT -->
</html>
